The estimated Net Worth of Reid M Huber is at least $6.04 Milhão dollars as of 3 January 2023. Reid Huber owns over 87,196 units of Bellicum Pharmaceuticals Inc stock worth over $11,450 and over the last 10 years he sold BLCM stock worth over $5,930,372. In addition, he makes $96,705 as Independent Director at Bellicum Pharmaceuticals Inc.
Sign up
Reid Huber BLCM stock SEC Form 4 insiders trading
Reid has made over 22 trades of the Bellicum Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 87,196 units of BLCM stock worth $6,518 on 3 January 2023.
The largest trade he's ever made was exercising 87,196 units of Bellicum Pharmaceuticals Inc stock on 3 January 2023 worth over $6,518. On average, Reid trades about 7,348 units every 68 days since 2014. As of 3 January 2023 he still owns at least 153,179 units of Bellicum Pharmaceuticals Inc stock.
You can see the complete history of Reid Huber stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Reid Huber biography
Dr. Reid M. Huber Ph.D. serves as Independent Director of the Company. Dr. Huber has served as a member of our Board since October 2014. Dr. Huber has served as a Partner at Third Rock Ventures since December 2018, where he focuses on discovering, launching and building innovative, value-creating, product engine-focused companies across multiple therapeutic areas. From April 2014 to December 2018, Dr. Huber served as at Executive Vice President and Chief Scientific Officer at Incyte Corporation, where he led drug discovery research primarily in the area of hematology and oncology. From 2002 to 2014, Dr. Huber held various roles of increasing responsibility at Incyte. Prior to joining Incyte, Dr. Huber held scientific research positions at DuPont Pharmaceuticals and Bristol-Myers Squibb from 1997 to 2002. Dr. Huber received his Ph.D. in molecular genetics from the Washington University School of Medicine and held pre- and post-doctoral fellowships at the National Institutes of Health. Our Board believes that Dr. Huber’s extensive background in the pharmaceutical industry and senior management experience qualify him to serve on our Board.
What is the salary of Reid Huber?
As the Independent Director of Bellicum Pharmaceuticals Inc, the total compensation of Reid Huber at Bellicum Pharmaceuticals Inc is $96,705. There are 6 executives at Bellicum Pharmaceuticals Inc getting paid more, with Richard Fair having the highest compensation of $1,732,890.
How old is Reid Huber?
Reid Huber is 48, he's been the Independent Director of Bellicum Pharmaceuticals Inc since 2014. There are 10 older and 5 younger executives at Bellicum Pharmaceuticals Inc. The oldest executive at Bellicum Pharmaceuticals Inc is Dr. Alan K. Smith Ph.D., 63, who is the Chief Scientific Officer.
What's Reid Huber's mailing address?
Reid's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, SUITE 1200, HOUSTON, TX, 77098.
Insiders trading at Bellicum Pharmaceuticals Inc
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli..., eJon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
What does Bellicum Pharmaceuticals Inc do?
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
What does Bellicum Pharmaceuticals Inc's logo look like?
Complete history of Reid Huber stock trades at Bellicum Pharmaceuticals Inc e Incyte
Bellicum Pharmaceuticals Inc executives and stock owners
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Richard Fair,
President, Chief Executive Officer, Director -
Richard A. Fair,
Pres, CEO & Director -
Shane Ward,
Corporate Secretary, Chief Legal and Strategy Officer -
Charity D. Scripture M.S., Pharm.D.,
Chief Devel. Officer -
James Brown,
Independent Chairman of the Board -
Jon Stonehouse,
Independent Director -
Reid Huber,
Independent Director -
Stephen Davis,
Independent Director -
Judith Klimovsky,
Independent Director -
James Daly,
Independent Director -
David Strauss,
Corporate Controller -
Aaron Foster,
Senior Vice President, Head of Research -
Atabak Mokari,
Chief Financial Officer -
Charity Scripture,
Chief Devel. Officer -
Dr. Aaron E. Foster,
Head of Research & Sr. VP -
Dr. Alan K. Smith Ph.D.,
Chief Scientific Officer -
Joseph Senesac,
Sr. VP of Technical Operations & Quality -
Charles S. Grass,
Principal Accounting Officer -
Alan A Musso,
CFO and Treasurer -
Thomas J. Farrell,
President and CEO -
Frank B. Mc Guyer,
Director -
Alan K. Smith,
EVP, Technical Operations -
Ken Moseley,
Vice President -
Kevin M. Slawin,
CMO and CTO -
Bros. Advisors Lpbaker Feli...,
-
Peter L. Hoang,
Sr. VP of Bus. Development -
Annemarie Moseley,
Chief Operating Office and EVP -
Rosemary Y. Williams,
VP, Finance & PAO -
Gregory S. Naeve,
Chief Business Officer -
Bros. Advisors Lp Baker Bro...,
-
Edmund Harrigan,
Director -
William Grossman,
Sr. VP, Chief Medical Officer -
David M. Spencer,
Chief Scientific Officer -
Jr Joseph Paul Woodard,
SVP Clinical & Medical Affairs -
Joseph Senesac,
VP of Manufacturing -
Investments Ltd. Mc Guyer,
10% owner -
Ventures Llc Remeditex,
10% owner -
Charity Scripture,
Chief Development Officer -
Bros. Advisors Lpbaker Juli...,